Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Potential interaction between troglitazone and atorvastatin.

L DiTusa1, A B Luzier

  • 1Department of Pharmacy Practice, 313 Cooke Hall, State University of New York at Buffalo School of Pharmacy, Buffalo, NY 14260-1200, USA.

Journal of Clinical Pharmacy and Therapeutics
|September 6, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A pharmacy-based approach to cholesterol management.

The American journal of managed care·2001
Same author

Acid-suppressive therapy use associated with antihypertensive agents.

Journal of clinical pharmacology·2001
Same author

Treatment of hypertension in a managed care setting.

The American journal of managed care·2001
Same author

Containment of heart failure hospitalizations and cost by angiotensin-converting enzyme inhibitor dosage optimization.

The American journal of cardiology·2000
Same author

Homocysteine as a risk factor for atherosclerosis.

The Annals of pharmacotherapy·2000
Same author

Gender-related effects on metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers.

Clinical pharmacology and therapeutics·1999

Troglitazone and atorvastatin combination therapy may increase LDL-cholesterol and triglycerides. This drug interaction warrants further investigation in diabetic patients with dyslipidemia.

Area of Science:

  • Pharmacology
  • Clinical Medicine
  • Drug Interactions

Background:

  • Troglitazone is a CYP3A4 isoenzyme inducer.
  • It can decrease plasma concentrations of CYP3A4 substrates.
  • Atorvastatin, a CYP3A4 substrate, is often co-prescribed with troglitazone for diabetic dyslipidemia.

Purpose of the Study:

  • To investigate the clinical effects of troglitazone on fasting lipid profiles.
  • To assess changes in patients receiving atorvastatin.

Main Methods:

  • Retrospective review of medical records for patients on concomitant troglitazone and atorvastatin.
  • Inclusion criteria: complete lab data, unchanged atorvastatin dose, stable diabetes regimen, ≥3 months of therapy, medication adherence.

Main Results:

Related Experiment Videos

  • Only 4 of 31 patients met inclusion criteria.
  • All were male, mean age 63, on insulin for diabetes.
  • Combination therapy showed a 23.3% increase in LDL-cholesterol and 21.3% increase in triglycerides.

Conclusions:

  • The observed increases in LDL-cholesterol and triglycerides suggest a drug interaction.
  • This interaction between troglitazone and atorvastatin requires further study.
  • Combination therapy may negatively impact lipid profiles in diabetic patients.